Table 6 (A) Matched-pair analysis, (B) matched-pair analysis: results; sAML per antecedent hematological disorder versus de novo AML

de novo

21.4% [17–26.1]

23.4% [19–28.1]

55.2% [49.5–60.5]

61.4% [55.7–66.5]

46.3% [40.7–51.6]

sAML

21% [15.1–27.5]

20.6% [15.1–26.8]

58.4% [50.6–65.4]

66.4% [58.8–73]

48.2% [40.4–55.6]

sAML versus de novo AML

0.98 (0.67–1.42)

0.92 (0.64–1.33)

0.95 (0.74–1.22)

0.91 (0.69–1.2)

0.92 (0.73–1.16)

p value (cluster = pair)

0.9

0.67

0.67

0.51

0.48

de novo

27.6% [23.2–32.1]

9.5% [6.9–12.7]

31.8% [26.7–37]

10.2% [7.2–13.8]

sAML

27.7% [21.6–34.1]

6.7% [3.7–10.8]

32.8% [25.7–40.1]

10.6% [6.4–16.1]

sAML versus de novo AML

0.99 (0.72–1.38)

0.7 (0.36–1.35)

1.03 (0.75–1.42)

0.93 (0.53–1.61)

p value (cluster = pair)

0.96

0.29

0.84

0.79

de novo AML

21.4% [17–26.1]

23.4% [19–28.1]

55.2% [49.5–60.5]

61.4% [55.7–66.5]

46.3% [40.7–51.6]

MDS/MPN/BMFS

21.5% [14.3–29.7]

17.2% [11–24.5]

61.3% [51.5–69.7]

70.7% [61.4–78.2]

47% [37.2–56.2]

OMHD/ST

19.9% [10.8–30.9]

27.1% [16.6–38.7]

53% [39.6–64.8]

58.6% [44.8–70.1]

50.1% [36.8–62]

MDS/MPN/BMFS versus de novo

HR (95% CI)

0.98 (0.63–1.52)

0.84 (0.53–1.31)

0.9 (0.67–1.22)

0.84 (0.6–1.18)

0.96 (0.74–1.25)

p value

0.92

0.44

0.5

0.33

0.76

OMHD/ST

HR (95% CI)

0.98 (0.55–1.75)

1.09 (0.64–1.84)

1.04 (0.7–1.53)

1.04 (0.69–1.58)

0.85 (0.58–1.24)

p value

0.94

0.75

0.85

0.85

0.4

de novo AML

27.6% [23.2–32.1]

9.5% [6.9–12.7]

31.8% [26.7–37]

10.2% [7.2–13.8]

MDS/MPN/BMFS

29.1% [21.5–37.2]

7.1% [3.5–12.4]

38.3% [29–47.5]

13.8% [7.8–21.4]

OMHD/ST

25% [15.4–35.8]

5.9% [1.9–13.3]

22.3% [12.5–33.9]

5% [1.3–12.8]

MDS/MPN/BMFS versus de novo

HR (95% CI)

1.05 (0.73–1.51)

0.75 (0.35–1.57)

1.24 (0.88–1.74)

1.22 (0.68–2.17)

p value

0.78

0.44

0.22

0.5

OMHD/ST

HR (95% CI)

0.88 (0.52–1.49)

0.62 (0.21–1.78)

0.67 (0.38–1.19)

0.42 (0.13–1.39)

p value

0.64

0.37

0.17

0.15